24/7 Wall Street
19 Jul 2026, 13:00 UTC · 15h ago
Why Johnson & Johnson Is a Stock You Can Own Forever
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
24/7 Wall Street
19 Jul 2026, 13:00 UTC · 15h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
Johnson & Johnson raised its full-year 2026 revenue guidance to between $100.3 billion and $101.3 billion, with adjusted EPS projected at $11.45 to $11.65. — Upwardly revised full-year guidance is a primary driver for stock price appreciation and indicates strong management confidence in growth.
+0.60JNJ reported Q1 2026 revenue of $24.06 billion, representing a 9.9% year-over-year increase. — Consistent top-line growth and EPS beats validate the company's ability to offset patent cliffs with new product growth.
+0.40The company generated $19.7 billion in free cash flow during full-year 2025. — Strong cash flow supports the sustainability of dividends, buybacks, and R&D investment, reducing financial risk.
+0.30Continue reading
6 related stories
Top 3 movers · tap to explore
Johnson & Johnson increased its quarterly dividend by 3.1% to $1.34 per share in April 2026, extending its growth streak to 64 years. — While positive for income investors, a modest dividend increase is expected for a Dividend King and has lower immediate price volatility impact.
+0.20Q1 2026 results included $330 million in litigation charges. — Litigation costs are a drag on earnings, though the article notes this is a minor factor compared to the overall long-term thesis.
-0.10Which stocks this story touches
Strongly praised for its 64-year dividend streak, diversified revenue, and robust free cash flow.
Mentioned positively for steady organic growth and a 63rd consecutive dividend increase.
Described as a stock worth owning for decades.
Presented unfavorably compared to JNJ due to a shorter dividend history and higher dependence on fewer blockbuster drugs.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
The Motley Fool
3h ago
